INmune Bio shares slide after Phase II Alzheimer’s trial misses endpoints
INmune Bio said that a subset of patients in the study showed clinical benefit from the therapy.
01 July 2025
01 July 2025
INmune Bio said that a subset of patients in the study showed clinical benefit from the therapy.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.